To further deepen the university-enterprise cooperation mechanism and precisely align with the talent demands of the biopharmaceutical industry, on April 8, 2026, a delegation of over twenty faculty members and students, led by Dean Han Junhai, visited the Taizhou Medical High-tech Zone (Gaogang District) for a specialized "Enterprise Visit & Career Development" exchange activity. The delegation was received by Zhao Guang, Vice District Mayor of Gaogang (a seconded official from our university), along with representatives from the Organization Department of the High-tech Zone Party Committee, the Pharmaceutical Industry Park Management Office, and executives from participating enterprises. Through site visits, symposiums, and policy briefings, the activity aimed to provide students and faculty with first-hand exposure to the frontiers of the biopharmaceutical industry, gain deep insights into talent requirements and regional recruitment policies, and jointly explore new models for collaborative education between the university, local government, and enterprises.

I. Entering China Medical City: Experiencing an Industrial Hub

        The delegation's first stop was the core exhibition area of China Medical City (CMC), where they systematically learned about the development of the Taizhou health industry. As the nation’s only national-level medical high-tech zone, China Medical City operates under the vision of being "First in China, Famous in the World," having established a complete ecosystem from R&D and incubation to industrialization. Guides detailed the industrial clusters, development history, and specialized support policies, and led the group through the functional layout of the International Precision Health Center. From vaccines and antibody drugs to diagnostic reagents, a vibrant industrial landscape unfolded, providing a solid foundation for industrial understanding for the subsequent visits.

        At the Human Resources Service Industrial Park, students and faculty gained an in-depth understanding of its "Government-Led, Market-Oriented, Professional Service" operational model. Park officials highlighted specialized support policies for biopharmaceutical talent, including recruitment subsidies, housing security, and the "CMC Elite" program, and provided a tour of the one-stop service hall and talent training base. The park expressed its commitment to actively building a bridge between Southeast University and key enterprises within the district to ensure precise delivery of talent policies. Students noted that such policy support increased their confidence in pursuing employment or entrepreneurship in Taizhou.

        At the Vaccine Engineering Center, the head of the center introduced the R&D progress of leading local vaccine enterprises such as GDL Biotechnology, AIM Action, Recbio, Ab&B Bio-Tech, Qyuns Therapeutics, and Boehringer Ingelheim, showcasing Taizhou’s cluster advantages in fields like influenza and herpes zoster vaccines. Subsequently, the delegation visited the Vaccine Evaluation Center to learn about its outstanding achievements in pre-clinical evaluation—research that has been published in top-tier journals such as The Lancet. Technical experts explained innovative vaccine technologies including novel adjuvants, antigen design, and delivery vectors. Additionally, the park houses the National Quality Inspection Center for Fine Chemicals, providing critical technical support for the vaccine industrial chain. Students deeply felt the significant responsibility of scientific innovation in safeguarding public health.

II. Deep Dive into Qyuns Therapeutics: Exploring the Blue Ocean of Antibody Drugs

        The delegation visited Jiangsu Qyuns Therapeutics and Cellularforce. Company leadership used the global "blockbuster" drug Humira as an example to illustrate the market scale of antibody drugs for autoimmune diseases, which exceeds 100 billion USD. Students then toured the antibody drug production process, from cell line development to formulation filling, where every step reflected the precision and rigor of modern biopharmaceutical manufacturing.

        During the corporate presentation, Dr. Kong introduced the full-chain technical route based on the antibody drug development platform, and Ms. Sun provided a detailed interpretation of the company’s talent policies, including competitive compensation systems, equity incentives, and dual-track career development paths. Students asked questions enthusiastically in a lively atmosphere. Both parties jointly unveiled the "Southeast University Employment and Internship Practice Base" and engaged in in-depth discussions with the High-tech Zone regarding collaborative education, joint graduate training, and the commercialization of scientific research findings.

III. Visiting BioPerfectus: Sensing the Future of Intelligent Diagnostics

        The final stop brought the delegation to Jiangsu BioPerfectus Biotech Co., Ltd.

        Through corporate videos and executive briefings, the group gained a comprehensive understanding of the company’s technical platforms and products under development in the field of in vitro diagnostics (IVD), such as infectious disease testing. Executives demonstrated vaginal microbiota evaluation systems, fully automated sample pretreatment solutions, intelligent laboratory solutions, and the integrated application of sample analysis solutions with third-party medical testing.

        During the technical presentation, experts shared BioPerfectus’s innovative achievements in molecular diagnostics and POCT (Point-of-Care Testing); the HR director detailed recruitment policies and job requirements. In the interactive session, students and faculty engaged in deep discussions with company leaders regarding technical R&D, career development, and internship opportunities. The School introduced the general overview of the university and the college, and both parties jointly unveiled the "Southeast University Employment and Internship Practice Base." Subsequently, the university, government, and enterprise representatives held pragmatic consultations on cooperation directions such as joint talent cultivation, collaborative technical breakthroughs, and precise matching of job positions, laying a solid foundation for long-term cooperation.

Conclusion

        This specialized activity in Taizhou is a vital practice for the School to engage with the industrial frontline and deepen the integration of industry and education. Through site visits, on-site learning, and interactive exchanges, students and faculty gained a comprehensive understanding of cutting-edge technologies and industrial trends in biopharmaceuticals, vaccines, antibody drugs, and in vitro diagnostics. This has allowed for a precise grasp of enterprise talent needs and further clarified directions for professional study and career paths.

        In the future, the School will continue to deepen long-term cooperation with key enterprises in Taizhou’s medical and health sectors, continuously building platforms for university-enterprise collaborative education. By promoting the deep integration of the education, talent, industrial, and innovation chains, the School aims to cultivate high-quality biopharmaceutical professionals and support high-quality employment for graduates.